Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002

Abstract

Although this study did not prove estramustine phosphate to be superior to placebo in terms of protocol end points, it generates the hypothesis that prolonged survival may be achieved with estramustine phosphate treatment in a subgroup of patients and that this may be predicted by a decrease in PSA after 1 month of therapy.